TABLE 4
FROM:
Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults
H Narimatsu, S Terakura, K Matsuo, T Oba, T Uchida, H Iida, M Hamaguchi, M Watanabe, A Kohno, M Murata, M Sawa, K Miyamura and Y Morishita for the Nagoya Blood and Marrow Transplantation Group (NBMTG)
BACK TO ARTICLETable 4. Prognostic factors of post-CBT immune reactionsa
| Univariate factors | HR | 95|[percnt]| CI | P-value |
|---|---|---|---|
| Age (years) | 1.00 | 0.98|[ndash]|1.01 | 0.69 |
| Sex (female vs male) | 1.26 | 0.70|[ndash]|2.26 | 0.44 |
| Risk of underlying diseases (high vs low) | 0.73 | 0.40|[ndash]|1.35 | 0.32 |
| Previous transplantb | 1.13 | 0.52|[ndash]|2.48 | 0.75 |
| Blood-type mismatch | 1.00 | 0.50|[ndash]|2.03 | 0.99 |
| Conditioning regimen (reduced-intensity vs myeloablative) | 0.72 | 0.40|[ndash]|1.28 | 0.26 |
| GVHD prophylaxis (with short-term MTX vs without short-term MTX) | 0.55 | 0.31|[ndash]|0.98 | 0.04 |
| Number of infused nuclear cells (>2 |[times]| 107 vs |[les]|2 |[times]| 107|[sol]|kg) | 0.89 | 0.40|[ndash]|1.96 | 0.77 |
| HLA matching (4|[sol]|6 vs 5|[ndash]|6|[sol]|6) | 0.87 | 0.48|[ndash]|1.56 | 0.63 |
| Step-wise multivariate factor | |||
| |[emsp]|GVHD prophylaxis (with short-term MTX vs without short-term MTX) | 0.55 | 0.31|[ndash]|0.98 | 0.04 |
Abbreviations: CBT|[equals]|cord blood transplantation; 95|[percnt]| CI|[equals]|95|[percnt]| confidence interval; GVHD|[equals]|graft-versus-host disease; HLA|[equals]|human leukocyte antigen; HR|[equals]|hazard ratio; MTX|[equals]|methotrexate; TBI|[equals]|total body irradiation.
a Those included PIR, ES and grade II|[ndash]|IV acute GVHD.
b Previous transplant included autologous and allogeneic hematopoietic stem cell transplantation.
